Vis enkel innførsel

dc.contributor.authorBischof, Katharinaen_US
dc.contributor.authorKnappskog, Stianen_US
dc.contributor.authorHjelle, Sigrun Margretheen_US
dc.contributor.authorStefansson, Ingunnen_US
dc.contributor.authorWoie, Kathrineen_US
dc.contributor.authorSalvesen, Helgaen_US
dc.contributor.authorGjertsen, Bjørn Toreen_US
dc.contributor.authorBjørge, Lineen_US
dc.PublishedBischof K, Knappskog S, Hjelle SM, Stefansson IM, Woie K, Salvesen H, Gjertsen BT, Bjørge L. Influence of p53 isoform expression on survival in high-grade serous ovarian cancers. Scientific Reports. 2019;9:5244eng
dc.description.abstractHigh-grade serous ovarian carcinoma (HGSOC) is characterised by alterations in the p53 pathway. The expression levels of p53 isoforms have been shown to be associated with patient survival in several cancers. This study examined the predictive and prognostic effects of the expression levels of TP53 pre-mRNA splicing isoforms and TP53 mutations in tumour tissues in 40 chemotherapy responders and 29 non-responders with HGSOC. The mRNA expression levels from total p53, and total Δ133p53, p53β, p53γ isoforms were determined by RT-qPCR, and TP53 mutation status by targeted massive parallel sequencing. The results from these analyses were correlated with the clinical outcome parameters. No differential expression of p53 isoforms could be detected between the chemosensitive and chemoresistant subgroups. In a multivariate Cox regression model, high levels of total Δ133p53 were found to be an independent prognosticator for improved overall survival (HR = 0.422, p = 0.018, 95% CI: 0.207–0.861) and reached borderline significance for progression-free survival (HR = 0.569, p = 0.061, 95% CI: 0.315–1.027). TP53 mutations resulting in loss of function or located at known hotspots were predictive of tumour characteristics and disease progression. These findings suggest that total Δ133p53 mRNA can be a biomarker for survival in HGSOC.en_US
dc.rightsAttribution CC BYeng
dc.titleInfluence of p53 isoform expression on survival in high-grade serous ovarian cancersen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2019 The Author(s)
dc.source.journalScientific Reports

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY